Table 2 Association of EGFR expression with clinicopathologic parameters in prostatic acinar adenocarcinoma
n(%) | P-Value | |||
|---|---|---|---|---|
Positive (n = 23) | Negative (n = 100) | |||
Age Groups | ≤70 years | 14(60.9) | 63(63) | 0.849 |
> 70 years | 9(39.1) | 37(37) | ||
Total gleason score | 6 | 1(4.3) | 38(38) | < 0.001 |
7 | 3(13) | 26(26) | ||
8 | 5(21.7) | 22(22) | ||
9 | 14(60.9) | 14(14) | ||
WHO grade groupª | Grade 1 | 1(4.3) | 38(38) | < 0.001 |
Grade 2 | 2(8.7) | 23(23) | ||
Grade 3 | 1(4.3) | 3(3) | ||
Grade 4 | 5(21.7) | 22(22) | ||
Grade 5 | 14(60.9) | 14(14) | ||
Tumor Quantificationª | < 10% | 1(4.3) | 22(22) | 0.007 |
10–50% | 3(13) | 32(32) | ||
> 50% | 19(82.6) | 46(46) | ||
Perineural invasion | Present | 16(69.6) | 30(30) | < 0.001 |
Absent | 7(30.4) | 70(70) | ||
Lymphovascular invasionª | Present | 0(0) | 3(3) | 1.000 |
Absent | 23(100) | 97(97) | ||
Extraprostatic extensionª | Present | 0(0) | 7(7) | 0.346 |
Absent | 23(100) | 93(93) | ||
Seminal vesicle invasion ª | Present | 2(8.7) | 2(2) | 0.158 |
Absent | 21(91.3) | 98(98) | ||
Recurrence | Yes | 19(82.6) | 14(14) | < 0.001 |
No | 4(17.4) | 86(86) | ||